Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18894152 | 0.75 | DAO (0.36) | ALDH1A1TLR8 | |
| SCHEMBL3323208 | 0.73 | TLR8 (0.37) | ALDH1A1KMT2ATLR8CYP11B1CYP11B2 | |
| SCHEMBL18894190 | 0.72 | ALDH1A1 (0.34) | ALDH1A1TLR8 | |
| SCHEMBL1826324 | 0.72 | AURKA (0.35) | ALDH1A1TLR8 | |
| SCHEMBL18894161 | 0.72 | ALDH1A1 (0.34) | ALDH1A1TLR8 | |
| SCHEMBL18894154 | 0.70 | ALDH1A1 (0.34) | ALDH1A1GAATLR8HSD17B10MAPT | |
| SCHEMBL18894130 | 0.70 | ALDH1A1 (0.40) | ALDH1A1TSHRKMT2ATLR8 | |
| SCHEMBL18894151 | 0.69 | ALDH1A1 (0.33) | ALDH1A1TLR8 | |
| SCHEMBL18894202 | 0.68 | TSHR (0.33) | ALDH1A1TSHRKMT2ATLR8MEN1 | |
| SCHEMBL18894132 | 0.64 | KDM4E (0.40) | GAATSHRKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | UCB Biopharma SRL (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | CELLTECH R&D LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| EP-3380464-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089453-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | PEPD, ADAM17, ANPEP | ALDH1A1 3365/4885GAA 2807/4885TSHR 4748/4885 |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | PEPD, ADAM17, ANPEP | ALDH1A1 3365/4885GAA 2807/4885TSHR 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.